Dupixent in the treatment of infantile eczema patients reaches the phase 3 clinical endpoint

On August 30, 2021, Sanofi and Regeneron announced that the dupilumab injection (dupilumab, English trade name), jointly developed by the two companies, will be treated for 6 months.

Duplizumab is a fully human monoclonal antibody that can inhibit the signal transduction of interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways

The primary endpoint in this phase 3 trial is the proportion of patients achieving complete or almost clear skin symptoms (IGA score of 0 or 1), and the proportion of patients achieving a 75% improvement in the area and severity index of eczema (EASI-75)

In the trial, the drug showed safety results similar to its known safety profile for the treatment of atopic dermatitis

AD is a chronic type 2 inflammatory disease, 85%-90% of patients are younger than 5 years old

Reference materials:

[1] Dupixent® (dupilumab) pivotal trial meets all primary and secondary endpoints becoming first biologic medicine to significantly reduce signs and symptoms of moderate-to-severe atopic dermatitis in children as young as 6 months.